Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages

  Kocijan, Roland ^a   Muschitz, Christian ^a   Fahrleitner Pammer, Astrid ^d   Amrein, Karin ^d   Pietschmann, Peter ^b   Haschka, Judith ^a   Dinu, Sebastian ^c   Kapiotis, Stylianos ^c   Resch, Heinrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Institute of Central Laboratory   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BIOLOGICAL MARKERS; BODY COMPOSITION; BODY MASS INDEX; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; FEMALE; FRACTURES, BONE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOGENESIS IMPERFECTA; PROCOLLAGEN;

EID: 84893737543     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2244     Document Type: Article

References (42)

1. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7:540-557.
2. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101-116.
3. Kocijan R, Muschitz C, Fratzl-Zelman N, et al. Femoral geometric parameters and BMD measurements by DXA in adult patients with different types of osteogenesis imperfecta. Skeletal Radiol. 42:187-194.
4. Moester MJ, Papapoulos SE, LowikCW,van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010;87:99-107.
5. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280:26770-26775.
6. Ohyama Y, Nifuji A, Maeda Y, Amagasa T, Noda M. Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. Endocrinology. 2004;145:4685-4692.
7. Modder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26:373-379.
8. Amrein K, Amrein S, Drexler C, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012; 97:148-154.
9. Gaudio A, Pennisi P, Bratengeier C, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010;95:2248-2253.
10. Spatz JM, Fields EE, Divieti Pajevic P, et al. Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab. 2012;97:E1736-E1740.
11. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011;26:2812-2822.
12. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013; 24:489-494.
13. Szulc P, Bertholon C, Borel O, Marchand F, Chapurlat R. Lower fracture risk in older men with higher sclerostin concentration-A prospective analysis from the MINOS study. J Bone Miner Res. 2013;28(4):855-864.
14. Arasu A, Cawthon PM, et al. Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab. 2012; 97:2027-2032.
15. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the center of excellence for osteoporosis research study. J Bone Miner Res. 2012;27:2592-2602.
16. Sheng Z, Tong D,OuY, et al. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol (Oxf). 2012;76: 797-801.
17. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24:578-588.
18. Lim V, Clarke BL.Newtherapeutic targets for osteoporosis: beyond denosumab. Maturitas. 2012;73:269-272.
19. Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Sclerostin antibody improves skeletal parameters in a Brtl/- mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013; 28:73-80.
20. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-The six-month effect of risedronate and teriparatide. Osteoporos Int. 2012;23:1171-1176.
21. Niemann I, Hannemann A, NauckM,et al. The association between insulin-like growth factor I and bone turnover markers in the general adult population. Bone. 2013;56:184-190.
22. Koivula MK, Laitinen P, Risteli J. Evaluation of IDS-iSYS intact parathyroid hormone (iPTH) and comparison to Siemens Advia Centaur iPTH assay in chronic renal failure patients and in controls. Clin Lab. 2012;58:403-410.
23. Koivula MK, Matinlassi N, Laitinen P, Risteli J. Four automated 25-OH total vitamin D immunoassays and commercial liquid chromatography tandem-mass spectrometry in Finnish population. Clin Lab. 2013;59:397-405.
24. Schmidt-Gayk H, Spanuth E, Kotting J, et al. Performance evaluation of automated assays for -CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin Chem Lab Med. 2004;42:90-95.
25. Hind K, Oldroyd B, Truscott JG. In vivo precision of the GE Lunar iDXA densitometer for the measurement of total body composition and fat distribution in adults. Eur J Clin Nutr. 2011;65:140-142.
26. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000;26:581-589.
27. Uveges TE, Collin-Osdoby P, Cabral WA, et al. Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J Bone Miner Res. 2008;23:1983-1994.
28. Osipenkova-Vichtomova TK. [Bone tissue in osteogenesis imperfecta: light and electron microscopic studies]. Arkhiv Patologii. 2006;68:20-25.
29. McKiernan FE. Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult. Osteoporos Int. 2005;16:1698-1702.
30. Balkefors V, Mattsson E, Pernow Y, Saaf M. Functioning and quality of life in adults with mild-To-moderate osteogenesis imperfecta [published online December 27, 2012]. Physiother Res Int. doi: 10.1002/pri.1546.
31. Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E, Viapiana O, Adami S. Bone turnover markers in patients with osteogenesis imperfecta. Bone. 2004;34:1013-1016.
32. Basel D, Steiner RD. Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. GenetMed. 2009; 11:375-385.
33. Cundy T, Horne A, Bolland M, Gamble G, Davidson J. Bone formation markers in adults with mild osteogenesis imperfecta. Clin Chem. 2007;53:1109-1114.
34. Garnero P, Schott AM, Prockop D, Chevrel G. Bone turnover and type I collagen C-Telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations. Bone. 2009; 44:461-466.
35. Delmas PD, Munoz F, Black DM, et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009;24:1544-1551.
36. Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007;356:1075-1076.
37. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002;86:356-364.
38. Bradbury LA, Barlow S, Geoghegan F, et al. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int. 2012;23:285-294.
39. Chung YE, Lee SH, Lee SY, et al. Long-Term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int. 2012;23:1235-1243.
40. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone. 2012;50:739-742.
41. Robling AG, Niziolek PJ, Baldridge LA, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008;283:5866-5875.
42. Folkestad L, Hald JD, Hansen S, Gram J, Langdahl B, Abrahamsen B, Brixen K. Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT. J Bone Miner Res. 2012;27:1405-1412.